Cytomos, a biotechnology company based in Edinburgh, Scotland, has raised £5 million in an oversubscribed funding round led by existing investors Archangels with participation from Old College Capital, Scottish Enterprise and British Business Bank.

The funds will be used to scale up production of its unique cell analysis technology, AuraCyt, and will enable the company to drive sales of its first commercial product, Celledonia (built on AuraCyt). Celledonia is a benchtop cell analyser which aims to enhance single-cell analysis.
With intentions set on establishing a foothold in North America, the company has a pipeline of trials planned with global partners.